NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera

Press/Media

Period	23 May 2023

Media coverage

Title	NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera
Media name/outlet	Pharmaceutical Daily
Country/Territory	Bosnia and Herzegovina
Date	23/05/23
URL	https://pharmaceuticaldaily.com/nccn-clinical-practice-guidelines-in-oncology-updated-to-recommend-besremi-ropeginterferon-alfa-2b-njft-as-a-preferred-intervention-for-polycythemia-vera/
Persons	John Mascarenhas